Sanofi Australia has received
TGA approval for its Zaltrap
(aflibercept rch) in combination
with irinotecan-fluoropyrimidinebased
chemotherapy for use in
adults with metastatic colorectal
cancer previously treated with an
oxaliplatin-containing regimen.
In Australia, colorectal cancer is
the second most common cancer in
both men and women.
Zaltrap is a recombinant fusion
protein which acts as a decoy
receptor binding to growth factors
related to angiogenesis.The above article was sent to subscribers in Pharmacy Daily's issue from 05 Apr 13 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 05 Apr 13
THE role and significance of community pharmacy in regional areas was a key focus of discussion for the Nationals leader David Littleproud during last week’s visit to Orana Mall Pharmacy as part of a regional tour.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.